Orforglipron
ATTAIN-2
Eli Lilly · Phase 3 · Completed · Enrollment 1613
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | 24.4% | 7% | 1.9% | n/r |
| 6 mg Orforglipron QD | 49.8% | 23.9% | 7.3% | n/r |
| 12 mg Orforglipron QD | 60.2% | 35.5% | 17.7% | n/r |
| 36 mg Orforglipron QD | n/r | n/r | n/r | n/r |
Not shown
- 36 mg Orforglipron QD: endpoint not reported